Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfhydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: A method of processing data for comparing at least two images using data processing elements, includes extracting a first sample of coordinate values (X1, . . . , Xn1) from at least one first image (Im1) and a second sample of coordinate values (Y1, . . . , Yn2) from at least one second image (Im2). A normal score value (Z) is then computed, with the processing elements, based on a density test statistic function ({circumflex over (T)}) applied on the first and second samples of coordinate values, wherein this density test statistic function has an asymptotic distribution, and a p-value, derived from the computed normal score value (Z), is compared (400) with a predetermined level of significance (?) in order to determine a similarity between the two images. The method can be used for determining the influence and assessing the cytotoxicity of a compound, monitoring a drug treatment, determining cellular morphology changes and the influence of an infection by pathogens.

Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B-X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B-X are also included.

Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: —STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: The invention pertains to methods for using chimeric polypeptides of the formula: B—X wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B—X are also included.

Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.

Abstract: The invention concerns a polypeptide sequence comprising the fragment B of Shiga toxin or a functional equivalent thereof bound at the carboxy-terminal end with one or several polypeptides corresponding to the formula B−X in which B represents the fragment B of the Shiga toxin and X represents one or several polypeptides of therapeutic interest, and its use as active principle in a therapeutic composition.

Abstract: The invention pertains to chimeric polypeptides of the formula: B—X   wherein B represents the B fragment of Shiga toxin or a functional equivalent thereof, and X represents one or more polypeptides of therapeutic significance. Compositions for therapeutic use comprising the polypeptide B—X are also included.

Abstract: A process for the immunobacteriological detection of pathogenic germs possessing specific antigenic determinants, and a kit for carrying out the process, with the aid of a magnetic gel to which are coupled anti-specific antigenic determinant antibodies, characterized by the following steps:(a) a biological medium supposedly contaminated by a pathogenic germ possessing a specific antigenic determinant is brought into contact with particles of the magnetic gel,(b) the particles of magnetic gel are then removed by magnetic means and(c) are inoculated onto a nutrient agar medium,(d) the agar medium is incubated to develop culture colonies of the pathogenic germs;(e) areas containing serum containing antibodies specific to the pathogenic germ to be detected are formed in the agar,(f) the germs are lysed by means of lysing agents,(g) the lysate is incubated with the serum for a time enabling the serological antibody-antigen reaction to take place by immunodiffusion on the agar, and(h) the quantity of germs containe